2021. Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s55. DOI:https://doi.org/10.25251/skin.5.supp.55.